Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients
Authors
Keywords
-
Journal
CANCER
Volume 120, Issue 24, Pages 3923-3931
Publisher
Wiley
Online
2014-08-09
DOI
10.1002/cncr.28953
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice
- (2013) Marta Garcia et al. BJU INTERNATIONAL
- VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
- (2013) P Orlandi et al. BRITISH JOURNAL OF CANCER
- Castrate-resistant prostate cancer
- (2013) Song Zhao et al. CURRENT OPINION IN UROLOGY
- Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer
- (2013) Irene Cardillo et al. Future Oncology
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
- (2013) J. Vuky et al. ONCOLOGIST
- Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
- (2013) John Araujo et al. Cancer Management and Research
- Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer
- (2012) Noel W. Clarke BJU INTERNATIONAL
- Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
- (2012) L. Eng et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature
- (2011) T. Nelius et al. CANCER TREATMENT REVIEWS
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Metronomic Chemotherapy for Metastatic Prostate Cancer
- (2010) Andrea Fontana et al. DRUGS & AGING
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
- (2010) Andrea Fontana et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
- (2009) A. Fontana et al. CLINICAL CANCER RESEARCH
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
- (2009) L. Jain et al. MOLECULAR CANCER THERAPEUTICS
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
- (2008) Scott D. Solomon et al. CIRCULATION
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started